Topic: Next generation targeted therapies: drugging the undruggable oncogene KRAS and reactivating P53

Kevan Shokat

    Dr. Kevan M. Shokat is currently an Investigator of the Howard Hughes Medical Institute, Professor in the Department of Cellular and Molecular Pharmacology at the University of California at San Francisco and Professor in the Department of Chemistry at the University of California at Berkeley.  He received his B.A. in Chemistry from Reed College in 1986, his Ph.D. in organic chemistry at UC Berkeley with Professor Peter Schultz and carried out post-doctoral work in cellular immunology at Stanford University with Professor Chris Goodnow. Kevan’s research group is focused on the discovery of new small molecule tools and drug candidates targeting protein/lipid kinases, GTPases, and RNA helicases. His laboratory utilizes the tools of synthetic organic chemistry, protein engineering, structural biology, biochemistry and cell biology. He was inducted into the National Academy of Sciences (2010), the National Academy of Medicine (2011), and the American Academy of Arts and Sciences (2011).  He has commercialized discoveries from his laboratory through co-founding several biotechnology companies including Intellikine, Araxes, Wellspring Biosciences, Kura Oncology, eFFECTOR Therapeutics, Mitokinin, Revolution Medicines, Erasca and Kumquat Biosciences.

Back to top